| Schedule of segment reporting information |
The following table presents information by reportable operating segment for the three and six months ended June 30, 2021 and 2020 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Products
Segment |
|
Specialty Pharmaceutical Segment |
|
Consolidated Totals |
| Three months ended June 30, 2021: |
|
|
|
|
|
| Product sales, net |
$ |
5,128 |
|
|
$ |
— |
|
|
$ |
5,128 |
|
|
|
|
|
|
|
| Gross profit |
$ |
2,290 |
|
|
$ |
— |
|
|
$ |
2,290 |
|
| Research and development expense |
126 |
|
|
99 |
|
|
225 |
|
| Selling, general and administrative expense |
5,565 |
|
|
10 |
|
|
5,575 |
|
| Operating loss |
$ |
(3,401) |
|
|
$ |
(109) |
|
|
$ |
(3,510) |
|
|
|
|
|
|
|
| Three months ended June 30, 2020: |
|
|
|
|
|
| Product sales, net |
$ |
5,396 |
|
|
$ |
— |
|
|
$ |
5,396 |
|
|
|
|
|
|
|
| Gross profit |
$ |
2,322 |
|
|
$ |
— |
|
|
$ |
2,322 |
|
| Research and development expense |
152 |
|
|
594 |
|
|
746 |
|
| Selling, general and administrative expense |
6,180 |
|
|
53 |
|
|
6,233 |
|
| Operating loss |
$ |
(4,010) |
|
|
$ |
(647) |
|
|
$ |
(4,657) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer Products
Segment |
|
Specialty Pharmaceutical Segment |
|
Consolidated Totals |
| Six months ended June 30, 2021: |
|
|
|
|
|
| Product sales, net |
$ |
9,972 |
|
|
$ |
— |
|
|
$ |
9,972 |
|
|
|
|
|
|
|
| Gross profit |
4,648 |
|
|
— |
|
|
4,648 |
|
| Research and development expense |
254 |
|
|
157 |
|
|
411 |
|
| Selling, general and administrative expense |
10,835 |
|
|
25 |
|
|
10,860 |
|
| Operating loss |
$ |
(6,441) |
|
|
$ |
(182) |
|
|
$ |
(6,623) |
|
|
|
|
|
|
|
| Six months ended June 30, 2020: |
|
|
|
|
|
| Product sales, net |
$ |
13,666 |
|
|
$ |
— |
|
|
$ |
13,666 |
|
|
|
|
|
|
|
| Gross profit |
6,330 |
|
|
— |
|
|
$ |
6,330 |
|
| Research and development expense |
457 |
|
|
1,798 |
|
|
2,255 |
|
| Selling, general and administrative expense |
13,990 |
|
|
62 |
|
|
$ |
14,052 |
|
| Operating loss |
$ |
(8,117) |
|
|
$ |
(1,860) |
|
|
$ |
(9,977) |
|
|